1. Home
  2. LGI vs VYGR Comparison

LGI vs VYGR Comparison

Compare LGI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$17.77

Market Cap

233.6M

Sector

N/A

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.13

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGI
VYGR
Founded
2004
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.6M
227.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LGI
VYGR
Price
$17.77
$4.13
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
46.9K
452.7K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
7.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$34.04
Revenue Next Year
N/A
$7.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.32
$2.65
52 Week High
$19.88
$5.55

Technical Indicators

Market Signals
Indicator
LGI
VYGR
Relative Strength Index (RSI) 56.15 55.77
Support Level $17.24 $3.71
Resistance Level $19.30 $4.31
Average True Range (ATR) 0.25 0.19
MACD 0.05 0.03
Stochastic Oscillator 66.67 75.78

Price Performance

Historical Comparison
LGI
VYGR

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: